Surgery
Volume 145, Issue 6 , Pages 587-590 , June 2009

The American College of Surgeons Oncology Group

  • Y. Nancy You, MD, MHSc

      Affiliations

    • Department of Surgery, Mayo Clinic, Rochester, MN
    • ,
  • David Ota, MD

      Affiliations

    • American College of Surgeons Oncology Group (ACOSOG), Durham, NC
    • ,
  • Heidi Nelson, MD

      Affiliations

    • Department of Surgery, Mayo Clinic, Rochester, MN
    • American College of Surgeons Oncology Group (ACOSOG), Durham, NC
    • Corresponding Author InformationReprint requests: Heidi Nelson, MD, American College of Surgeons Oncology Group (ACOSOG), Division of Colorectal Surgery, Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

,Accepted 10 March 2009.

References 

  1. NCI's clinical trials cooperative group program. Available from: http://www.cancer.gov/cancertopics/factsheet/NCI/clinical-trials-cooperative-group. Accessed June 1, 2008.
  2. You YN, Jacobs L, Martinez ED, Budinger SC, Wittlief EJ, Myles SK, et al. Improved surgeon performance in clinical trials: an analysis of quality assurance audits from the American College of Surgeons Oncology Group. J Am Coll Surg. 2006;203:269–276
  3. The American College of Surgeons Oncology Group (ACOSOG). Available from: https://www.acosog.org. Accessed June 1, 2008.
  4. Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE, Landreneau RJ, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81:1013–1020
  5. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–3663
  6. DeMatteo R, Owzar K, Maki R, Pisters P, Blackstein M, Antonescu C, et al. Adjuvant imitanib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. J Clin Onc. 2007;25:10079
  7. Picozzi V, Abrams R, Traverso L, O'Reilly E, Greeno E, Martin R, et al. ACOSOG Z05031: report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon. J Clin Oncol. 2008;26:4505
  8. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355:570–580
  9. Newman LA, Lee CT, Parekh LP, Stewart AK, Thomas CR, Beltran RA, et al. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Cancer. 2006;106:188–195
  10. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. Ann Surg. 2007;245:726–733

PII: S0039-6060(09)00142-1

doi: 10.1016/j.surg.2009.03.009

Surgery
Volume 145, Issue 6 , Pages 587-590 , June 2009

Article Tools